Make Speed, Simplicity and Reliability your competitive advantage.
Alfa Cytology's integrated CRO solutions streamline your R&D process.
Leukemia are blood cancers of which there are several variants and corresponding features. It’s this variation that leads scientists to design special treatments for each one.
Comprehensive Leukemia SpecialistWE SOLVE YOUR CHALLENGES IN
NO MATTER WHERE YOU ARE IN
LEUKEMIA SMALL MOLECULE DRUG DEVELOPMENT
We Offer Customized Solutions for You
Online Inquiry NowMeet the complex demands of innovative drug development
for different promising targets
PROTEIN KINASE INHIBITORs are being developed as new anti-tumor treatments to inhibit dysregulated signal transduction in leukemia.
- FLT3 inhibitor development
- IDH inhibitor development
- BCL-2 inhibitor development
- BCR-ABL inhibitor development
- BTK inhibitor development
- PI3K inhibitor development
IMMUNE CHECKPOINT INHIBITORs have been engineered as therapies for immune checkpoint failure in leukemia cells and immune escape in the cancers.
>> View details
HYPOMETHYLATING AGENT DEVELOPMENT may provide innovative solutions for breakthrough approaches to leukemia research and therapy, since gene mutations that involve methylation are implicated in the condition.
- DNA Methyltransferase (DNMT) inhibitor development
- Ten-eleven Translocation (TET) inhibitor development
HEDGEHOG PATHWAY INHIBITORs suppress the overexpression of the Hedgehog (Hh) signaling pathway in leukemia, which is associated with the maintenance of leukemia stem cells, thereby affect the outcome of patients.
- Smoothened (SMO) inhibitor development
- GLI inhibitor development
TARGETED DRUG DEVELOPMENT AGAINST HTLV-1 to find innovative treatments and improve prognosis for adult T-cell leukemia (ATL).
- Against transactivator from the X-gene region (Tax)
- Against HTLV-1 basic leucine zipper factor (HBZ)
LEUKEMIA CELL SURFACE ANTIGENs play an important role in diagnosing and classifying the disease and can also serve as binding sites for the development of targeted therapeutic approaches.
- Small molecule inhibitors targeting cell surface antigens
- Other targeted therapy development
Streamlined Small Molecule Drug R&D Process
Initial Consultation & Needs Assessment
Beginning with an initial consultation, we get a deep insight into your specific project requirements to make sure our services are completely compatible with your goals and compliances.
Tailored Proposal Development
Following discussion, we build you a one-to-one proposal for scope, approach, timeline and costing, specifically suited to your drug development needs.
Preclinical Drug Development & Quality Assurance
Preclinical drug development and validation is carried out by our team using advanced tools and techniques. All the way through, we have strict quality assurance processes so that the output can be reliable and accurate.
Findings Delivery & Reporting
Once the project is complete, we deliver a full report including all of the results, expert insights and takeaways. We validate that the report is as promised to you and meets all regulatory expectations before finalizing.
Ongoing Support Commitment
We do not stop after you have finished your project, we will support you with the next analysis or changes as your project evolves.
Select Services of Interest
"We have collaborated with Alfa Cytology on a leukemia drug development program and their expertise has contributed significantly to the success of the program. Their commitment to scientific integrity and excellence is unmatched. "
Taylor B., Director of Product Development
"Alfa Cytology's capabilities in small molecule drug development provided us with the innovative solution we were looking for. The support of their team was invaluable! "
Josh K., Chief Scientific Officer